罗莫索珠单抗相关药物治疗的颌骨坏死

Q3 Dentistry Oral and Maxillofacial Surgery Cases Pub Date : 2023-06-01 DOI:10.1016/j.omsc.2023.100318

Benjamin Palla , John Anderson , Michael Miloro , Sarah Moles , Nicholas Callahan

{"title":"罗莫索珠单抗相关药物治疗的颌骨坏死","authors":"Benjamin Palla , John Anderson , Michael Miloro , Sarah Moles , Nicholas Callahan","doi":"10.1016/j.omsc.2023.100318","DOIUrl":null,"url":null,"abstract":"<div><p>This is the first reported case of medication-related osteonecrosis of the jaw (MRONJ) resulting from the use of romosozumab, a new anti-resorptive medication that functions through inhibition of sclerostin. It was approved by the FDA in 2019, and mentioned in the 2022 AAOMS Position Paper on MRONJ. Although initial evidence from animal studies and clinical trials showed a low risk of MRONJ from romosozumab, recent publications on adverse event monitoring demonstrate the need for continued observation and research. Little is known regarding the risk of MRONJ from romosozumab, however, oral surgeons will inevitably be first line clinicians to manage patients on this medication. The purpose of this extremely unusual case report is to improve knowledge and heighten awareness about the association between romosozumab and MRONJ.</p></div>","PeriodicalId":38030,"journal":{"name":"Oral and Maxillofacial Surgery Cases","volume":"9 2","pages":"Article 100318"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Romosozumab-associated medication-related osteonecrosis of the jaw\",\"authors\":\"Benjamin Palla , John Anderson , Michael Miloro , Sarah Moles , Nicholas Callahan\",\"doi\":\"10.1016/j.omsc.2023.100318\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>This is the first reported case of medication-related osteonecrosis of the jaw (MRONJ) resulting from the use of romosozumab, a new anti-resorptive medication that functions through inhibition of sclerostin. It was approved by the FDA in 2019, and mentioned in the 2022 AAOMS Position Paper on MRONJ. Although initial evidence from animal studies and clinical trials showed a low risk of MRONJ from romosozumab, recent publications on adverse event monitoring demonstrate the need for continued observation and research. Little is known regarding the risk of MRONJ from romosozumab, however, oral surgeons will inevitably be first line clinicians to manage patients on this medication. The purpose of this extremely unusual case report is to improve knowledge and heighten awareness about the association between romosozumab and MRONJ.</p></div>\",\"PeriodicalId\":38030,\"journal\":{\"name\":\"Oral and Maxillofacial Surgery Cases\",\"volume\":\"9 2\",\"pages\":\"Article 100318\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral and Maxillofacial Surgery Cases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2214541923000275\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Dentistry\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral and Maxillofacial Surgery Cases","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2214541923000275","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Dentistry","Score":null,"Total":0}

引用次数: 1

摘要

这是首次报道的由使用romosozumab引起的药物相关性颌骨骨坏死(MRONJ)病例，romosozumab是一种通过抑制硬化蛋白起作用的新型抗吸收药物。它于2019年获得FDA批准，并在2022年AAOMS关于MRONJ的立场文件中提到。尽管来自动物研究和临床试验的初步证据显示，romosozumab产生MRONJ的风险较低，但最近发表的不良事件监测报告表明，需要继续进行观察和研究。关于romosozumab的MRONJ风险知之甚少，然而，口腔外科医生将不可避免地成为第一线临床医生来管理使用这种药物的患者。这一极不寻常的病例报告的目的是提高对romosozumab和MRONJ之间关联的认识和认识。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Romosozumab-associated medication-related osteonecrosis of the jaw

This is the first reported case of medication-related osteonecrosis of the jaw (MRONJ) resulting from the use of romosozumab, a new anti-resorptive medication that functions through inhibition of sclerostin. It was approved by the FDA in 2019, and mentioned in the 2022 AAOMS Position Paper on MRONJ. Although initial evidence from animal studies and clinical trials showed a low risk of MRONJ from romosozumab, recent publications on adverse event monitoring demonstrate the need for continued observation and research. Little is known regarding the risk of MRONJ from romosozumab, however, oral surgeons will inevitably be first line clinicians to manage patients on this medication. The purpose of this extremely unusual case report is to improve knowledge and heighten awareness about the association between romosozumab and MRONJ.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oral and Maxillofacial Surgery Cases Medicine-Otorhinolaryngology

CiteScore

0.60

自引率

0.00%

发文量

审稿时长

69 days

期刊介绍： Oral and Maxillofacial Surgery Cases is a surgical journal dedicated to publishing case reports and case series only which must be original, educational, rare conditions or findings, or clinically interesting to an international audience of surgeons and clinicians. Case series can be prospective or retrospective and examine the outcomes of management or mechanisms in more than one patient. Case reports may include new or modified methodology and treatment, uncommon findings, and mechanisms. All case reports and case series will be peer reviewed for acceptance for publication in the Journal.